Floatz logo

21 assets in Portal Hypertension

Therapeutic assets addressing Portal Hypertension, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carvedilol
Portal Hypertension
West China HospitalP4BBB (76)
Simvastatin
Portal Hypertension
Kafrelsheikh UniversityP4BBB (73)
Apsolol
Portal Hypertension
West China HospitalP4BBB (72)
Apixaban
Portal Hypertension
Asian Institute Of Medical SciencesP4BB (69)
Dipyridamole
Portal Hypertension
Northern Jiangsu People's HospitalP4BB (68)
Lactulose
Portal Hypertension
University of MichiganP4BB (68)
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)
Portal Hypertension
General Hospital of Shenyang Military RegionP4BB (65)
Rifaximin
Portal Hypertension
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)P4BB (65)
Alverine
Portal Hypertension
Shanghai Changzheng HospitalP2/3B (57)
Zinc Acexamate
Portal Hypertension
Hospital Universitari Vall d'Hebron Research InstituteP3B (57)
Atorvastatin
Portal Hypertension
Samsung Medical CenterP2CCC (53)
Durvalumab
Portal Hypertension
University of CincinnatiP2CCC (53)
Empagliflozin
Portal Hypertension
Boehringer IngelheimP2CCC (53)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
Portal Hypertension
University of CincinnatiP2CCC (53)
Lenvatinib
Portal Hypertension
Tongji HospitalP2CCC (53)
Metformin
Portal Hypertension
Assistance Publique - Hôpitaux de ParisP2CCC (53)
Tislelizumab
Portal Hypertension
Tongji HospitalP2CCC (53)
Fentanyl
Portal Hypertension
Hepatopancreatobiliary Surgery Institute of Gansu ProvinceN/AD (30)
Sulfur Hexafluoride
Portal Hypertension
Fondazione Policlinico Universitario Agostino Gemelli IRCCSN/AD (30)
Avenciguat
Portal Hypertension
Boehringer IngelheimP2D (29)